Methods 33 patients were accepted clozapine treatment only and followed 3 years by regular clinic visits. Using the BPRS, TESS to evaluate the efficacy.
方法对33例接受氯氮平治疗的精神分裂症患者进行定期门诊随访3年，并以简明精神病评定量表(BPRS)、副反应量表(TESS)进行疗效和副反应评定。
Results: After 9 months, the family psychological intervention therapy had obviously lower scores in BPRS and score of insight.
结果：经9个月的家庭心理干预后，干预组bprs总分及自知力因子分与药物组相比明显降低。
With activities of daily living (ADL), capable of living conditions of the two groups were assessed with the Brief Psychiatric Rating Scale (BPRS) the prognosis of patients were observed.
采用日常生活能力量表（ADL）对两组患者生活能力情况进行评定，并用简明精神病评定量表（BPRS）观察两组患者的预后。
Method Patients with first-onset schizophrenia were treated with risperidone for 12 weeks, and assessed with BPRS and TESS for the efficacy and side effect.
方法单独使用维思通治疗连续住院的首发精神分裂症12周，用BPRS和TESS量表评定疗效和副反应。
Clinical symptoms were assessed before and after the treatment period, using the Brief Psychiatry Rating Scale (BPRS).
之前和之后的治疗期间，使用简短的精神病评定量表(BPRS)，临床症状进行评估。
According to BPRS factor analysis, the retardation, activation and hostile suspiciousness was more obvious than other factors.
BPRS因子分析，对迟滞、活动过多、敌对猜疑较其它因子明显。
Therapeutic efficacy was measured by BPRS and the adverse reaction was rated by TESS. Steady serum level was monitored within 1, 2, 4, 6 week.
疗效和不良反应分别用简明精神病评定量表（BPRS）和副反应量表（TESS）进行评定，并测定治疗第1，2，4，6周的稳态血药浓度。
Method: 32 patients with first episode schizophrenia were treated with olanzapine for 8 weeks, and assessed with BPRS and TESS for the efficacy and safety.
方法用奥氮平治疗首发精神分裂症32例，疗程8周；用简明精神病评定量表(BPRS)和副反应量表(TESS)评定疗效及副反应。
Analysis of multiple stepwise regressions showed the main factors influencing patients' quality of life were BPRS, SAS, TESS and the duration of disease.
多因素逐步回归分析显示，影响患者生存质量的主要因素依次为BPRS、SAS、TESS和病程。
Methods: 64 chronic schizophrenic patients were treated with musical therapy and the effect was assessed with BPRS, SANS and NOSIE before and after the treatment.
方法：选取64例精神分裂症病人进行了音乐治疗前后对照研究，进行了BPRS、SANS、NOSIE的测定。
Brief psychiatric Rating Scale (BPRS) and Positive and Negative Syndrome Scale (PANSS) were used to assess the effects.
采用简明精神病量表(BPRS)、阳性和阴性症状量表(PANSS)进行评价。
No difference was found in the decreased score of BPRS between chlorpromazine group and clozapine group, however, the increased score of TESS decreased significantly(P<0.01).
氯氮平组BPRS减分值与氯丙嗪组无显著差别，但TESS增分值明显降低（P＜0 ．01） ；
The patients were assessed by brief psychiatric rating scale (BPRS), inpatient psychiatric rehabilitation outcome scale (IPROS) and general self-efficacy scale (GESE).
评定工具用简明精神病评定量表(BPRS)、住院精神病人康复疗效评定量表(IPROS)和自我效能感量表(GESE)进行对照评定分析。
The efficacy and safety were assessed with AIMS, BPRS and TESS at the end of week 1,2,4 and 6.
采用异常不自主运动量表（AIMS）和简明精神病评定量表（BPRS）及副反应量表（TESS）在治疗前及治疗后1、2、4、6周末分别评定疗效及不良反应。
The brief psychiatric rating scale (BPRS) was used to evaluate the effect, treatment emergent symptom scale (TESS) to evaluate side effects, and all the patients were followed up for 2 years.
用简明精神症状量表(BPRS)和药物副反应量表(TESS)评定疗效和副反应，治疗结束后随访两年。
The brief psychiatric rating scale (BPRS) was used to evaluate the effect, treatment emergent symptom scale (TESS) to evaluate side effects, and all the patients were followed up for 2 years.
用简明精神症状量表(BPRS)和药物副反应量表(TESS)评定疗效和副反应，治疗结束后随访两年。
应用推荐